Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma
Haofei Liu,Qiwen Zhao,Leyong Tan,Xin Wu,Rui Huang,Yonglin Zuo,Longjuan Chen,Jigui Yang,Zuo-Xin Zhang,Wenchen Ruan,Jiayang Wu,Fei He,Yiliang Fang,Fangyuan Mao,Peipei Zhang,Xiaoning Zhang,Peidi Yin,Zexuan Yan,Wenwen Xu,Huimin Lu,Qingrui Li,Mei Liang,Yanjun Jia,Cong Chen,Senlin Xu,Yu Shi,Yi-Fang Ping,Guang-Jie Duan,Xiao-Hong Yao,Zhijian Han,Tao Pang,Youhong Cui,Xia Zhang,Bo Zhu,Chunjian Qi,Yan Wang,Sheng-Qing Lv,Xiu-Wu Bian,Xindong Liu
DOI: https://doi.org/10.1016/j.ccell.2023.03.004
IF: 50.3
2023-04-11
Cancer Cell
Abstract:Malignant gliomas are largely refractory to immune checkpoint blockade (ICB) therapy. To explore the underlying immune regulators, we examine the microenvironment in glioma and find that tumor-infiltrating T cells are mainly confined to the perivascular cuffs and express high levels of CCR5, CXCR3, and programmed cell death protein 1 (PD-1). Combined analysis of T cell clustering with T cell receptor (TCR) clone expansion shows that potential tumor-killing T cells are mainly categorized into pre-exhausted/exhausted and effector CD8 + T subsets, as well as cytotoxic CD4 + T subsets. Notably, a distinct subpopulation of CD4 + T cells exhibits innate-like features with preferential interleukin-8 (IL-8) expression. With IL-8-humanized mouse strain, we demonstrate that IL-8-producing CD4 + T, myeloid, and tumor cells orchestrate myeloid-derived suppressor cell infiltration and angiogenesis, which results in enhanced tumor growth but reduced ICB efficacy. Antibody-mediated IL-8 blockade or the inhibition of its receptor, CXCR1/2, unleashes anti-PD-1-mediated antitumor immunity. Our findings thus highlight IL-8 as a combinational immunotherapy target for glioma.
oncology,cell biology